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ABSTRACT
Background Bronchoscopy using endobronchial
ultrasound (EBUS) can help to diagnose small peripheral
pulmonary lesions. However, although biopsy sites can
be conﬁrmed, a bronchoscope cannot be guided in
EBUS. Virtual bronchoscopic navigation (VBN) can guide
a bronchoscope with virtual images, but its value has not
been conﬁrmed.
Methods This prospective multicentre study examines
the value of VBN-assisted EBUS for diagnosing small
peripheral pulmonary lesions. 199 patients with small
peripheral pulmonary lesions (diameter #30 mm) were
randomly assigned to VBN-assisted (VBNA) or
non-VBN-assisted (NVBNA) groups. A bronchoscope
was introduced into the target bronchus of the VBNA
group using the VBN system. Sites of specimen sampling
were veriﬁed using EBUS with a guide sheath under
ﬂuoroscopy.
Results The diagnostic yield was higher for the VBNA
than for the NVBNA group (80.4% vs 67.0%; p¼0.032).
The duration of the examination and time elapsed until
the start of sample collection were reduced in the VBNA
compared with the NVBNA group (median (range), 24.0
(8.7e47.0) vs 26.2 (11.6e58.6) min, p¼0.016) and 8.1
(2.8e39.2) vs 9.8 (2.3e42.3) min, p¼0.045,
respectively). The only adverse event was mild
pneumothorax in a patient from the NVBNA group.
Conclusions The diagnostic yield for small peripheral
pulmonary lesions is increased when VBN is combined
with EBUS.
Clinical trial number UMIN000000569.
INTRODUCTION
Lung cancer is the leading cause of cancer death in
Europe, the USA and Japan.
1e3 Although imaging
modalities including CT, MRI and positron emis-
sion tomography have been applied, pathological
ﬁndings remain the benchmark for a diagnosis of
lung cancer. The increased frequency of high
quality CT application has allowed the identiﬁca-
tion of much smaller and far more pulmonary
lesions than before.
4
Suspected malignant pulmonary lesions can be
diagnosed by bronchoscopy, but the sensitivity of
detecting small peripheral lung cancer varies from
36% to 86% depending on the size of the lesion.
5e7
According to the lung cancer diagnosis and treat-
ment guidelines issued by the American College of
ChestPhysicians(ACCP),
8thediagnosticsensitivity
of bronchoscopy for peripheral pulmonary lesions is
78%, whereas that for lesions <2 cm is 34%. In
comparison, the reported diagnostic sensitivity of
transthoracic needle aspiration (TTNA) is 90%, and
TTNA is recommended for diagnosing lesions
<2 cm. Consequently, TTNA is frequently applied
in many countries, but the incidence of complica-
tions is fairly high. The British Thoracic Society
(BTS) guidelines state that the incidence of pneu-
mothorax is 0e61%, with chest tube drainage
required in 3.3e15%, intrapulmonary haemorrhage
in 5e16.9% and haemoptysis in 1.25e5%.
9 The
ACCPguidelinesstatewithrespecttobronchoscopy
that,‘.inexperthands,aradialprobeUSdevicecan
increase the diagnostic yield of FB while dealing
with peripheral lesions of <20 mm in size. Its use
can be considered prior to referring the patient for
TTNA.’ The given grade of recommendation is 2B.
8
Target lesions can be directly visualised by EBUS
before attempting biopsies that raise the diagnostic
yields for peripheral lesions
10; reported diagnostic
yields are 58.3e80%.
10e13 However, EBUS cannot
navigate the bronchoscope itself, so lesions cannot
be reached in 8e20.8% of cases.
11 13
Navigational bronchoscopy has recently
improved the diagnostic approach to peripheral
small lesions. Electromagnetic navigation (EMN) is
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Lung cancerone of two methods that are currently in clinical use, and one
EMN system (inReach System; superDimension, Minneapolis,
Minnesota, USA) has been marketed mainly in Europe and in
the USA.
14 Bronchoscopists navigate EMN systems using
a positional sensor that determines direction based on an elec-
tromagnetic ﬁeld generated around the patient’s chest. Reported
diagnostic yields of EMN for variously sized peripheral pulmo-
nary lesions range from 69% to 74%.
15e17 A randomised study
has shown that EMN-assisted bronchoscopy combined with
EBUS is more sensitive than either modality alone (diagnostic
yield, 88% vs 69% and 59%, respectively).
18
Virtual bronchoscopic navigation (VBN) is another method in
which virtual bronchoscopic images of the bronchial path to
a peripheral lesion are generated and used as a guide to navigate
the bronchoscope.
19 Since virtual bronchoscopic (VB) and bron-
choscopic images are similar, the bronchoscope can be advanced
near a target lesion according to the bronchial pathway displayed
on the VB images. AVBN system has been developed that allows
the automatic production of virtual images of the bronchial path
that are matched with actual images for reliable bronchoscopic
navigation to sampling sites.
20 21 However, the value of VBN has
not yet been clearly and statistically demonstrated. The present
multicentre, prospective, randomised study examines the value of
VBN-assisted EBUS for diagnosing small peripheral pulmonary
lesions of suspected lung cancer.
METHODS
Participants
We enrolled 199 patients who were referred to three Japanese
medical centres between April 2006 and August 2007 with
peripheral pulmonary lesions (mean diameter #3 cm calculated
from axial CT images) suspected to be cancer that were not
pathologically conﬁrmed. Peripheral pulmonary lesions were
deﬁned as those that are surrounded by normal lung paren-
chyma and thus unlikely to be visualised by bronchoscopy. Most
of these lesions were discovered by plain chest x-rays and/or CT
images acquired for reasons other than the symptoms caused by
the lesions. Eligible patients were men and women $20 years
old who could tolerate bronchoscopy. The exclusion criteria
comprised evidence of endobronchial disease revealed by chest
CT, percutaneous oxygen saturation <90%, a range of known
severe co-morbid conditions (unstable angina, acute myocardial
infarction within the past 3 months, severe asthma or uncon-
trolled pulmonary infection), pregnancy and unable to proceed
without anticoagulant or antiplatelet medications. We moni-
tored the course of lesions that were <10 mm with ground-glass
opacity conﬁrmed by CTand excluded them from the study.
Randomisation and intervention
Eligible patients were randomly assigned to VBN-assisted
(VBNA) or non-VBN-assisted (NVBNA) groups. Because others
have shown that bronchoscopic diagnostic yield is associated
with lesion size
8 and physician skill, randomisation was based
on lesion size (mean diameter <2c m o r 2 e3 cm) and bron-
choscopists used a randomised block design to ensure that these
factors were balanced in the study arms. Independent, blinded,
trial staff randomly assigned the patients before bronchoscopy.
Scan data from multidetector chest CT (16- or 64-row; slice
width, 0.5e2 mm) were acquired from all patients without
using contrast medium before bronchoscopy. Individual CT data
sets from the VBNA group were transferred to a workstation on
which VBN software automatically created virtual broncho-
scopic images
21 within 20 min. The consecutive images could be
moved forwards and backwards and rotated like a bronchoscope
in a monitor positioned beside the video-bronchoscopic screen in
the endoscopy suite. As assistant physician controlled the virtual
bronchoscopic images
20 during bronchoscopy and a bronchosco-
pist inserted an endoscope as instructed (ﬁgure 1). All patients
were locally anaesthetised with lidocaine and examined using
a thin video-bronchoscope (type P260F; outer diameter, 4.0 mm;
Olympus Medical Systems, Tokyo, Japan). Additional pentazo-
cine hydrochloride or hydroxyzine chloride was administered as
required.
Bronchoscopic insertion was assisted using the VBN system in
the VBNA group. The bronchoscope was introduced into the
bronchus of the NVBNA group without VBN support and with
reference only to CT axial images. Lesions were visualised in
both groups by inserting a 20 MHz mechanical radial-type EBUS
probe (external diameter, 1.4 mm; UM-S20-17S; Olympus
Medical Systems) with a guide sheath (K-201; Olympus Medical
Figure 1 Virtual bronchoscopic navigation. An assistant physician controls virtual bronchoscopic images of the path leading to a peripheral lesion and
a bronchoscopist inserts an endoscope as instructed.
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Lung cancerSystems) through an endoscopic channel. This probe was
withdrawn as soon as the lesion was visualised. Pathological
samples were collected using forceps and/or a brush introduced
into the guide sheath.
12 If the lesion was not visualised by EBUS,
the approach to sampling was decided by the bronchoscopist.
The area around the bronchial target was washed as determined
by the bronchoscopist with 20 ml of saline as a supplementary
procedure. Biopsy samples were immediately ﬁxed in formalin,
brush smears on glass slides were immediately ﬁxed in alcohol,
and pathologists who were blinded to the results of random-
isation processed and evaluated all specimens using standard
procedures. The presence of bacteria was assessed in some
portions of brush smears and/or lavage. All patients were posi-
tioned on an x-ray table, correct device placement was conﬁrmed
and sampling was conducted under ﬂuoroscopy.
Outcomes
The primary end point was bronchoscopic diagnostic yield
deﬁned as all instances in which the results matched the ﬁnal
diagnosis conﬁrmed by pathological and/or bacterial assessment
of bronchoscopic samples. The key secondary end point was
total examination duration, which was calculated as the interval
between the moment the endoscope passed the vocal cords until
its withdrawal from the trachea. Other secondary end points
were the interval until the start of sample collection, duration of
x-ray ﬂuoroscopy and the generation number of the inserted
bronchi. A segmental bronchus was deﬁned as third generation.
Safety end points of interest included severe haemorrhage,
pneumothorax, hypoxaemia, lidocaine intoxication, arrhythmia,
pneumonia and other serious adverse events. Retrieved blood
loss >50 ml mixed with or without saline lavage was deﬁned as
signiﬁcant. The safety of all patients was assessed.
Study follow-up
If a lesion was undiagnosed by bronchoscopy, we recommended
that the patient consider undergoing other diagnostic proce-
dures, including CT-guided ﬁne needle aspiration (FNA) or
surgical intervention. If an undiagnosed patient refused further
intervention, follow-up was considered as the second best
strategy. Thus, this study continued until the last enrolled
patient had been followed up for 2 years. Follow-up information
was derived from outpatient clinics, by telephone or by fax
contact.
Statistical analysis
Sample size was calculated based on the primary end point.
The estimated diagnostic yields in the VBNA and NVBNA
groups based on published records were 70% and 50%, respec-
tively.
13 21 22 Thus, at 80% power and a¼0.05, we calculated
that 190 patients would be required (n¼95 in each group) to
determine whether diagnostic yield improved with the addition
of VBNA. We planned to enrol 200 patients to account for
incomplete data or undiagnosed patients.
We analysed the diagnostic yield and safety of the entire
intent-to-treat population. Data from the per-protocol popula-
tion that included all randomised patients with planned bron-
choscopic procedures for peripheral lesions were also statistically
analysed. Primary and secondary variables were analysed using
Figure 2 CONSORT ﬂow diagram. *All
allocated patients were included in the
intention-to-treat population. yDiagnoses
established without operating virtual
bronchoscopic navigation (VBN). zThe
bronchoscopic procedure was performed
according to protocol. xFinal diagnosis of
this patient was not established;
however, this patient was included in the
per-protocol analysis.
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Lung cancerthe Pearson c
2 test and the ManneWhitney U test. Continuous
variables were assessed for normality in distribution and the
ManneWhitney test/description as medians was used. All
p values were two-sided. A p value of <0.05 indicated statistical
signiﬁcance. All data were statistically analysed using IBM SPSS
Statistics, V 18.
RESULTS
We randomly assigned 102 and 97 patients to the VBNA and
NVBNA groups. One and two patients in the NVBNA and
VBNA groups, respectively, with endobronchially visible malig-
nant or large (>3 cm) lesions were ineligible. We could not use
VBN in one patient in the VBNA group and another refused
bronchoscopy after assignment to the NVBNA group. We
excluded these ﬁve patients from the per-protocol populations.
The trial proﬁle is shown in ﬁgure 2. Age, sex, lesion size and
location in patients at baseline were similar between the groups
(table 1).
The proportions of primary lung cancer, other malignancies
and non-malignant diseases were similar between the groups.
Non-malignant diseases comprised tuberculosis, non-tubercu-
lous mycobacterial infection, fungal disease, organising pneu-
monia, hamartoma and lipoma. Among bronchoscopically
undiagnosed patients, 23 (44.2%) of 52 underwent video-assisted
thoracoscopy and/or surgery and 8 (15.4%) were diagnosed by
CT-guided FNA or repeated bronchoscopy. Twenty of the 21
patients who refused further intervention were followed up for
2 years.
The results indicated a signiﬁcant difference in diagnostic
yield between arms both in the intent-to-treat (all randomly
assigned patients, n¼199) and the per-protocol populations
(ﬁnally analysed patients, n¼194). Diagnostic yield was signiﬁ-
cantly higher for the VBNA than for the NVBNA groups in both
the intent-to-treat (82 (80.4%) of 102 vs 65 (67.0%) of 97;
p¼0.032) and per-protocol (80 (80.8%) of 99 vs 64 (67.4%) of 95;
p¼0.032; table 2) populations.
Diagnostic yield did not differ signiﬁcantly according to lesion
size between the groups in the per-protocol population (table 3).
Of the virtual images constructed based on data from the
VBNA group, 98% agreed with actual images of the shape of
each bronchial bifurcation on the route. The median generation
of virtual bronchial images was six (range, 4e12 bronchi).
The VBN system thus allowed insertion of the endoscope into
signiﬁcantly further generations of bronchi (VBNA vs NVBNA
median (range): 4 (2e8) vs 4 (2e7); p<0.001; table 4). The
endoscope was also accurately positioned in the VBNA group,
with more targets being conﬁrmed by EBUS (VBNA vs NVBNA:
92/99 (92.9%) vs 77/95 (81.1%); p¼0.014). Numbers of biopsies
and brushings/washes did not differ signiﬁcantly between the
groups. Total examination duration was signiﬁcantly shorter in
the VBNA than in the NVBNA group (median (range): 24.0
(8.7e47.0) vs 26.2 (11.6e58.6) min; p¼0.016). The interval to
starting sample collection was signiﬁcantly shorter in the VBNA
versus the NVBNA group (8.1 (2.8e39.2) vs (9.8 (2.3e42.3) min;
p¼0.045). The duration of x-ray ﬂuoroscopy exposure did not
differ signiﬁcantly between the groups. No severe or moderate
adverse events were associated with bronchoscopy except for
mild pneumothorax that did not require chest drainage in
a patient from the NVBNA group.
DISCUSSION
This is the ﬁrst prospective, multicentre, randomised trial to
examine the value of using a VBN system to assist radial EBUS.
The ﬁndings showed that VBN-assisted EBUS with a guide
sheath signiﬁcantly improved the diagnostic yield of small
pulmonary peripheral lesions to 80.4%, which was 13% higher
than that in the NVBNA group (67.0%). The diagnostic yield for
similar lesions in our previous study using a conventional or thin
bronchoscope assisted by VBN under ﬂuoroscopy was 62.5%.
23
The diagnostic yield was 58.3% in another of our studies using
EBUS.
13 The high diagnostic yield in the present study was
achieved by combining these two procedures. Moreover,
although the study cohort was small and diagnostic yields for
lesions <20 mm did not differ signiﬁcantly, the diagnostic yield
with VBNA was nevertheless high at 75.9%. Comparison is
difﬁcult since x-ray ﬂuoroscopy was used in this study, but the
diagnostic yield with EBUS + VBN was comparable with that
reported by Eberhardt et al.
18 One advantage of VBN compared
with EMN is simplicity. Operations such as steering the sensor
Table 1 Baseline characteristics and ﬁnal diagnoses
VBNA group
(n[102)
NVBNA group
(n[97)
Age (years, median; range) 69 (21e85) 67 (27e82)
Male, n (%) 64 (62.7) 57 (58.8)
Lesion size (mm, median; range) 18.0 (9.5e30.0) 18.0 (7.0e30.0)
<20 mm, n (%) 59 (57.8) 59 (60.8)
20e30 mm, n (%) 43 (42.2) 38 (39.2)
Lesion location
Rt. upper lobe, n (%) 32 (31.4) 35 (36.1)
Rt. middle lobe, n (%) 12 (11.8) 6 (6.2)
Rt. lower lobe, n (%) 23 (22.5) 18 (18.6)
Lt. upper lobe, n (%) 25 (24.5) 21 (21.6)
Lt. lower lobe, n (%) 10 (9.8) 17 (17.5)
Final diagnosis
Malignant disease n (%)
Primary lung cancer n (%) 69 (67.6) 76 (78.4)
Other malignant disease n (%) 10 (9.8) 4 (4.1)
Non-malignant disease n (%)
Infectious disease n (%) 17 (16.7) 8 (8.2)
Other benign condition n (%) 5 (4.9) 9 (9.3)
Undetermined n (%) 1 (1.0) 0 (0)
Lt., left; NVBNA, non-virtual bronchoscopic navigation-assisted; Rt., right; VBNA, virtual
bronchoscopic navigation-assisted.
Table 2 Diagnostic yields in the intent-to-treat and per-protocol
populations
Bronchoscopic diagnosis
p Value VBNA NVBNA
Full intent-to-treat 82/102 (80.4) 65/97 (67.0) 0.032
Per-protocol 80/99 (80.8) 64/95 (67.4) 0.032
Data are shown as numbers of lesions/total lesions (%).
NVBNA, non-virtual bronchoscopic navigation-assisted; VBNA, virtual bronchoscopic
navigation-assisted.
Table 3 Diagnostic yield according to lesion size in the per-protocol
population
Lesion size
Bronchoscopic diagnosis
p Value VBNA NVBNA
<20 mm 44/58 (75.9) 35/59 (59.3) 0.056
20e30 mm 36/41 (87.8) 29/36 (80.6) 0.382
Total 80/99 (80.8) 64/95 (67.4) 0.032
Data are presented as numbers of lesions/total lesions (%).
NVBNA, non-virtual bronchoscopic navigation-assisted; VBNA, virtual bronchoscopic
navigation-assisted.
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Lung cancerprobe or registration during tests are not required to superim-
pose the electromagnetic sensor position and CT information as
with EMN.
14 Furthermore, the bronchoscope is advanced
together with virtual image indications in VBN, which is
essentially identical to conventional bronchoscope manipula-
tion.
19 Thus, bronchoscopists with basic skills can easily operate
this system after practice on a simulator. Locatable guides
attached to the EMN sensor probe are single use, which imposes
a cost burden of US$700e1000 per patient depending on market
price.
24
The diagnostic sensitivity of TTNA differs depending on the
technique and lesion size, but it is 92% with FNA under CT
guidance
6 and 82e90% even for lesions #2 cm. However, the
main complication with FNA under CT guidance is pneumo-
thorax, which occurs at an incidence of 15e42%
25e27 and is
quite frequent with small lesions or emphysema.
27 Reported
complications comprise bronchial haemorrhage,
25 needle tract
implantation and air embolism.
28 In contrast, the complication
rate with transbronchial lung biopsy is 0.2e5% for pneumo-
thorax and 1.2e9% for haemorrhage.
92 93 0Pneumothorax or
other complications have not been found in other studies of
EBUS + VBN to date, including the present study.
21 22 The
diagnostic sensitivity of EBUS + VBN may not be as high as
that with CT-guided FNA, but it is considerably higher than the
diagnostic sensitivity of normal bronchoscopy indicated in the
ACCP guidelines.
8 Therefore, considering the low rate of
complications, VBN combined with EBUS may be a viable
option for diagnosing small peripheral lesions.
To our knowledge, this is the ﬁrst report to describe the
duration of navigational bronchoscopy, and that the amount of
time required for guidance was decreased in the VBNA group.
Moreover, VBN improved diagnostic yield while decreasing the
overall duration of the examination by w2 min. This is thought
to be signiﬁcant in terms of patient comfort, especially consid-
ering that patients endured the procedure under local anaes-
thesia. Although the time required for ﬂuoroscopy tended to
decrease in the VBNA group, the difference did not reach
statistical signiﬁcance. Fluoroscopy duration before and after
initial sampling was not measured in this study, but almost all
of the ﬂuoroscopic exposure was taken up by specimen sampling
to conﬁrm proper device use, such as forceps opening and
cutting, as well as brushing at adequate sites. Steinfort et al
reported that radiation exposure from ﬂuoroscopy used together
with EBUS does not pose a clinical problem.
31 However, we
found that radiation exposure accounted for w40% of the total
duration of the examination. More reliable sampling devices are
needed for EBUS with a guide sheath.
We identiﬁed the following limitations. The precision of VB
decreases when CT data are inadequate during VB; for example,
the branch order that can be visualised is lower when slices are
too thick.
32 Under such circumstances, repeat CT might be
required, which imposes additional cost. Many of the patients
in this study were referred from private clinics after abnor-
malities on plain x-rays had been identiﬁed. Therefore, row CT
data with a slice thickness of #2 mm were collected from the
start with multidetector CT instruments at the institution
where the present study was conducted and, as a result, virtual
images could be created up to sixth generation bronchi. In
contrast, the amount of CT data increases with thinner slices
and more time is required to create VB images. Most of the
time required to create VB images in this study was due to PC
processing, but the VB images were created over a period of
w20 min. This depends to some extent on the performance of
the software and PC hardware, which could be further
enhanced. The VBN system used in the present study
(Bf-NAVI; Cybernet Systems, Tokyo, Japan) has been promoted
mainly in Japan. The automatic tracking system for the VBN
system used herein will allow automatic synchronisation of the
virtual to the actual bronchoscopic view.
33 Another VBN
system with an automatic tracking system has recently been
developed.
24 34 This study showed that diagnostic yield
improved with VBN when combined with EBUS which is still
not globally applied. We also combined VBN with ﬂuoroscopy,
and conﬁrmed lesions in 83% of patients with plain x-rays.
Although VBN has been applied without ﬂuoroscopy,
24 when
not combined with EBUS it is usually combined with CT
20 35
or ﬂuoroscopy
23 to conﬁrm lesions. Randomised studies with
each of these combinations may be necessary to deﬁne the
diagnostic value of VBN.
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Duration
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24.0 (8.7e47.0) 26.2 (11.6e58.6) 0.016
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8.1 (2.8e39.2) 9.8 (2.3e42.3) 0.045
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